Last reviewed · How we verify
Dalfampridine Pill
Dalfampridine Pill is a Potassium channel blocker Small molecule drug developed by D'Youville College. It is currently in Phase 2 development for Multiple sclerosis. Also known as: Physical Therapy.
Blocks potassium channels to enhance nerve conduction
Blocks potassium channels to enhance nerve conduction Used for Multiple sclerosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dalfampridine Pill |
|---|---|
| Also known as | Physical Therapy |
| Sponsor | D'Youville College |
| Drug class | Potassium channel blocker |
| Target | Voltage-gated potassium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Dalfampridine is a potassium channel blocker that increases the conduction velocity in the central nervous system, which is beneficial for patients with multiple sclerosis.
Approved indications
- Multiple sclerosis
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- Use of Dalfampridine in Primary Lateral Sclerosis (PHASE1)
- Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients (PHASE2, PHASE3)
- Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis (PHASE2, PHASE3)
- A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma (PHASE2, PHASE3)
- Ampyra for Optic Neuritis in Multiple Sclerosis (PHASE2, PHASE3)
- Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (PHASE4)
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy (PHASE2)
- A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dalfampridine Pill CI brief — competitive landscape report
- Dalfampridine Pill updates RSS · CI watch RSS
- D'Youville College portfolio CI
Frequently asked questions about Dalfampridine Pill
What is Dalfampridine Pill?
How does Dalfampridine Pill work?
What is Dalfampridine Pill used for?
Who makes Dalfampridine Pill?
Is Dalfampridine Pill also known as anything else?
What drug class is Dalfampridine Pill in?
What development phase is Dalfampridine Pill in?
What are the side effects of Dalfampridine Pill?
What does Dalfampridine Pill target?
Related
- Drug class: All Potassium channel blocker drugs
- Target: All drugs targeting Voltage-gated potassium channels
- Manufacturer: D'Youville College — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Multiple sclerosis
- Also known as: Physical Therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing